Nizatidine | LY-139037 | CAS#76963-41-2 | Histamine H2 Receptor Antagonist

MedKoo Cat#: 318375 | Name: Nizatidine

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Nizatidine is a histamine H2 receptor antagonist that inhibits stomach acid production. It is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease.

Chemical Structure

Nizatidine

CAS#76963-41-2

Theoretical Analysis

MedKoo Cat#: 318375

Name: Nizatidine

CAS#: 76963-41-2

Chemical Formula: C12H21N5O2S2

Exact Mass: 331.1137

Molecular Weight: 331.46

Elemental Analysis: C, 43.48; H, 6.39; N, 21.13; O, 9.65; S, 19.35

Price and Availability

Size	Price	Availability
5g	USD 350.00	2 Weeks
50g	USD 550.00	2 Weeks
100g	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Nizatidine, LY-139037, Tazac, Axid, LY 139037, LY139037

IUPAC/Chemical Name

(E)-N-(2-(((2-((dimethylamino)methyl)thiazol-4-yl)methyl)thio)ethyl)-N-methyl-2-nitroethene-1,1-diamine

InChi Key

NRFDOJHZMQJSKN-IZZDOVSWSA-N

InChi Code

InChI=1S/C12H21N5O2S2/c1-15(2)7-12-14-10(9-21-12)8-20-5-4-16(3)11(13)6-17(18)19/h6,9H,4-5,7-8,13H2,1-3H3/b11-6+

SMILES Code

CN/C(NCCSCC1=CSC(CN(C)C)=N1)=C\[N+]([O-])=O

Appearance

Off-white to light yellow-brown solid powder.

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Nizatidine is a potent and orally active histamine H2 receptor antagonist.

In vitro activity:

The present work entails the interaction of H2 blocker nizatidine with calf thymus (ct)-DNA for determining the binding mode and energetics of the interaction. Nizatidine was able to induce micronuclei formation and chromosomal damage at high dose. Additionally, cytotoxic activity of nizatidine was determined in cancer cell lines, namely HeLa and HCT-116 and compared with the normal human cell line HEK-293 employing MTT assay. Reference: J Biomol Struct Dyn. 2023 Feb;41(2):538-549. https://pubmed.ncbi.nlm.nih.gov/34856883/

In vivo activity:

The purpose of the present study was to formulate and characterize Nizatidine-encapsulated microballoons for enhancing bioavailability and increasing the residence time of drug in the gastrointestinal tract. In-vivo antiulcer activity was assessed by ethanol-induced ulcer in murine model. In ethanol-induced ulcer model, drug-loaded Microballoon-treated group showed significant (p < 0.01) ulcer protection index as compared to free drug-treated group. Reference: Drug Deliv. 2015 May;22(3):306-11. https://pubmed.ncbi.nlm.nih.gov/24601855/

	Solvent	mg/mL	mM
Solubility
	DMF	20.0	60.34
	DMSO	45.3	136.77
	Ethanol	8.5	25.64
	PBS (pH 7.2)	1.0	3.02
	Water	43.0	129.73

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 331.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Rahman Y, Afrin S, Perwez A, Ansari MO, Sarwar T, Ahmed S, Rizvi MA, Shadab GGHA, Tabish M. Nizatidine interacts with ct-DNA causing genotoxicity and cytotoxicity: an assessment by in vitro, in vivo, and in silico studies. J Biomol Struct Dyn. 2023 Feb;41(2):538-549. doi: 10.1080/07391102.2021.2008496. Epub 2021 Dec 3. PMID: 34856883. 2. Wang S, Wu B, Xue J, Wang M, Chen R, Wang B. Nizatidine, a small molecular compound, enhances killed H5N1 vaccine cell-mediated responses and protects mice from lethal viral challenge. Hum Vaccin Immunother. 2014;10(2):461-8. doi: 10.4161/hv.27165. Epub 2013 Nov 19. PMID: 24253609; PMCID: PMC4185914. 3. Jain A, Pandey V, Ganeshpurkar A, Dubey N, Bansal D. Formulation and characterization of floating microballoons of nizatidine for effective treatment of gastric ulcers in murine model. Drug Deliv. 2015 May;22(3):306-11. doi: 10.3109/10717544.2014.891273. Epub 2014 Mar 7. PMID: 24601855. 4. Ueki S, Seiki M, Yoneta T, Aita H, Chaki K, Hori Y, Morita H, Tagashira E, Itoh Z. Gastroprokinetic activity of nizatidine, a new H2-receptor antagonist, and its possible mechanism of action in dogs and rats. J Pharmacol Exp Ther. 1993 Jan;264(1):152-7. PMID: 8093722.

In vitro protocol:

In vivo protocol:

1. Jain A, Pandey V, Ganeshpurkar A, Dubey N, Bansal D. Formulation and characterization of floating microballoons of nizatidine for effective treatment of gastric ulcers in murine model. Drug Deliv. 2015 May;22(3):306-11. doi: 10.3109/10717544.2014.891273. Epub 2014 Mar 7. PMID: 24601855. 2. Ueki S, Seiki M, Yoneta T, Aita H, Chaki K, Hori Y, Morita H, Tagashira E, Itoh Z. Gastroprokinetic activity of nizatidine, a new H2-receptor antagonist, and its possible mechanism of action in dogs and rats. J Pharmacol Exp Ther. 1993 Jan;264(1):152-7. PMID: 8093722.

1: Haag S, Holtmann G. Onset of relief of symptoms of gastroesophageal reflux disease: post hoc analysis of two previously published studies comparing pantoprazole 20 mg once daily with nizatidine or ranitidine 150 mg twice daily. Clin Ther. 2010 Apr;32(4):678-90. doi: 10.1016/j.clinthera.2010.03.020. Review. PubMed PMID: 20435237. 2: Parente F, Bianchi Porro G. Acid inhibitory characteristics of nizatidine in man: an overview. Scand J Gastroenterol Suppl. 1994;206:3-7. Review. PubMed PMID: 7863250. 3: Romero M, Franzosi MG. [Nizatidine]. Medicina (Firenze). 1989 Jan-Mar;9(1):93-6. Review. Italian. PubMed PMID: 2567957. 4: Price AH, Brogden RN. Nizatidine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease. Drugs. 1988 Nov;36(5):521-39. Review. PubMed PMID: 2905640. 5: Zarling EJ. Prokinetic activity of nizatidine: implications for the management of patients with gastroesophageal reflux disease. Clin Ther. 1999 Dec;21(12):2038-46; discussion 2037. Review. PubMed PMID: 10645751. 6: German SV. [Nizatidine++ among the drugs usable in the treatment of acid-dependent gastric diseases]. Klin Med (Mosk). 1997;75(5):34-41. Review. Russian. PubMed PMID: 9235406. 7: Callaghan JT, Bergstrom RF, Rubin A, Chernish S, Crabtree R, Knadler MP, Obermeyer B, Offen WW, Schneck DW, Aronoff G, et al. A pharmacokinetic profile of nizatidine in man. Scand J Gastroenterol Suppl. 1987;136:9-17. Review. Erratum in: Scand J Gastroenterol Suppl 1991 Aug;26(8):preceding 801. PubMed PMID: 2892261. 8: Morton DM. Pharmacology and toxicology of nizatidine. Scand J Gastroenterol Suppl. 1987;136:1-8. Review. PubMed PMID: 2892249.